EVALUATION OF ACQUIRED OVEREXPRESSION OF HER2/neu ON CIRCULATING TUMOR CELLS IN PATIENTS WITH ADVANCED BREAST CANCER DURING CHEMOTHERAPY, AND ASSESSMENT OF ACTIVITY OF TRASTUZUMAB-BASED THERAPY: A PHASE II TRIAL.

Trial Profile

EVALUATION OF ACQUIRED OVEREXPRESSION OF HER2/neu ON CIRCULATING TUMOR CELLS IN PATIENTS WITH ADVANCED BREAST CANCER DURING CHEMOTHERAPY, AND ASSESSMENT OF ACTIVITY OF TRASTUZUMAB-BASED THERAPY: A PHASE II TRIAL.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2012

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top